Literature DB >> 34863388

Yes, It Does.

Nathan W Cummins1.   

Abstract

Entities:  

Year:  2021        PMID: 34863388      PMCID: PMC8633938          DOI: 10.1016/j.mayocp.2021.10.011

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


× No keyword cloud information.
We live in strange times, but the questions are not strange or new. My colleagues and I in Infectious Diseases and related specialties have heard them all before with other vaccines. For those who have access to the vaccine but remain unvaccinated against COVID-19 and are open to that possibility, a reductionist version of those myriad questions is simply, Does the vaccine work? Pani and colleagues address this simple question elegantly in their manuscript published in this issue of Mayo Clinic Proceedings, and the findings are even more relevant in the setting of increasing COVID-19 vaccine mandates. Their study is particularly noteworthy as it provides more “real-world” evidence of the effectiveness of the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in frontline health care workers in Milan, Italy, which has been hard-hit by the pandemic. If an unvaccinated health care worker were to ask me now, “Does the vaccine work?” I would hand the person this article by Pani et al and say simply, “Yes, it does.” Does it generate an immune response? The primary outcome of this prospective, observational cohort study was the measurement of total anti-spike IgG antibody levels and neutralizing antibody levels 14 days after the second injection. Acknowledging that the critical immunologic determinants of immune protection against COVID-19 have not yet been established, these 2 orthogonal serologic markers are standard and reasonable surrogates of immunogenicity of the vaccine. Remarkably, of the 2569 medical staff tested, only 4 (0.16%; 95% CI, 0.04% to 0.4%) were immunologic nonresponders based on antibody detection. This robust and pervasive immunogenicity has been confirmed in health care workers in Belgium. Does it work? Yes, it does. Does it protect from infection, disease, and death? The secondary outcome of this study was the frequency of symptomatic, polymerase chain reaction–positive COVID-19 after vaccination. As this was not a randomized clinical trial, the authors compare the rates of COVID-19 in the study participants with the concurrent epidemiologic curve in the region at the time. Only 13 of 5023 health care workers (0.26%) had a laboratory-confirmed breakthrough infection within the first few months after vaccination. This rate of early breakthrough infections is remarkably similar to those reported in Germany, the United Kingdom, and New York. Furthermore, the epidemiologic curves in Figure 3 of the manuscript by Pani et al demonstrate significantly reduced infection rates in vaccinated health care workers compared with the pre–vaccination period and compared with the general population in the third wave in Milan, similar to reports from Israel. Does it work? Yes, it does. Do the benefits outweigh the risks? All vaccines are subject to pharmacovigilance, or systemic monitoring of adverse effects on a population level. However, no vaccine has previously been scrutinized so thoroughly in so short a period as have the available COVID-19 vaccines, which have been administered in the billions of doses in less than a year. Comparatively, the sample of Pani et al of 1900+ vaccine recipient respondents reporting adverse events associated with the BNT162b2 vaccine is an almost insignificant drop in the ocean. However, consistent with much larger studies, serious adverse events were rare after the vaccine was received (<0.5%) in this study. Given the benefit of reduced COVID-19 infection from the vaccine, the benefits of vaccinating health care workers clearly exceed the risk. Does it work? Yes, it does. Will it work for me? This is the fundamental question for the vaccine-hesitant health care worker. Unfortunately, it is also fundamentally unanswerable. Pani et al describe several factors associated with reduced response to the BNT162b2 vaccine in health care workers, including age, sex, and immunosuppressed state. These are neither surprising nor modifiable and have been confirmed in other studies. It is notable that 22.7% of respondents self-reported 1 or more concomitant clinical conditions, reminding us that health care workers are susceptible to the same conditions that we treat in patients. The only difference is the degree of exposure to COVID-19. So, if a hesitant health care worker self-identifies a high personal risk of vaccine nonresponse, the logical conclusion should not be to avoid vaccination because of possible lack of benefit. The risk factors for vaccine nonresponse are the same for severe infection, and if there is increased risk of exposure, there is only one logical answer. Will it work for me? As the Magic Eight ball says, “Cannot predict now.” But better safe than sorry. Will it work forever? The study of Pani et al was not designed to address vaccine efficacy during a prolonged period. However, an affirmative answer to this very understandable question was never on the table. Viruses mutate and evolve. Immunity wanes. Babies are continuously born and are unprotected until vaccinated. Global and local disparities in access to vaccines persist. For these and other reasons, the SARS-CoV-2–susceptible pool is continually replenished. Infections continue, and the virus mutates to evade immunity. This is the same for all infections and vaccines. No vaccine works forever, individually or for a population. It is clear, though, that the BNT162b2 vaccine will not work forever. Despite persistence of detectable neutralizing antibodies up to 6 months after receipt of the related mRNA-1273 (Moderna) vaccine, the quantitative levels of these antibodies decline significantly. This is likely the same with the BNT162b2 vaccine. With the emergence and dominance of the delta SARS-CoV-2 variant, breakthrough infections in vaccinated health care workers increase. Will the available COVID-19 vaccines work forever? No, but that does not mean they are not useful in the present and for considerable but as yet unquantifiable periods into the future. President Biden announced on September 9, 2021, a COVID-19 vaccine mandate for health care workers at facilities receiving funds from Medicare and Medicaid. Vaccine mandates are not without controversy, and questions abound. However, one question has an answer. Does it work? Yes, it does.
  9 in total

1.  Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273.

Authors:  Deborah Steensels; Noella Pierlet; Joris Penders; Dieter Mesotten; Line Heylen
Journal:  JAMA       Date:  2021-10-19       Impact factor: 56.272

2.  Vaccine Breakthrough Infections with SARS-CoV-2 Variants.

Authors:  Ezgi Hacisuleyman; Caryn Hale; Yuhki Saito; Nathalie E Blachere; Marissa Bergh; Erin G Conlon; Dennis J Schaefer-Babajew; Justin DaSilva; Frauke Muecksch; Christian Gaebler; Richard Lifton; Michel C Nussenzweig; Theodora Hatziioannou; Paul D Bieniasz; Robert B Darnell
Journal:  N Engl J Med       Date:  2021-04-21       Impact factor: 91.245

3.  COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.

Authors:  Victoria Jane Hall; Sarah Foulkes; Ayoub Saei; Nick Andrews; Blanche Oguti; Andre Charlett; Edgar Wellington; Julia Stowe; Natalie Gillson; Ana Atti; Jasmin Islam; Ioannis Karagiannis; Katie Munro; Jameel Khawam; Meera A Chand; Colin S Brown; Mary Ramsay; Jamie Lopez-Bernal; Susan Hopkins
Journal:  Lancet       Date:  2021-04-23       Impact factor: 79.321

4.  BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers.

Authors:  Shmuel Benenson; Yonatan Oster; Matan J Cohen; Ran Nir-Paz
Journal:  N Engl J Med       Date:  2021-03-23       Impact factor: 91.245

5.  Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.

Authors:  Amarendra Pegu; Sarah E O'Connell; Stephen D Schmidt; Sijy O'Dell; Chloe A Talana; Lilin Lai; Jim Albert; Evan Anderson; Hamilton Bennett; Kizzmekia S Corbett; Britta Flach; Lisa Jackson; Brett Leav; Julie E Ledgerwood; Catherine J Luke; Mat Makowski; Martha C Nason; Paul C Roberts; Mario Roederer; Paulina A Rebolledo; Christina A Rostad; Nadine G Rouphael; Wei Shi; Lingshu Wang; Alicia T Widge; Eun Sung Yang; John H Beigel; Barney S Graham; John R Mascola; Mehul S Suthar; Adrian B McDermott; Nicole A Doria-Rose; Jae Arega; John H Beigel; Wendy Buchanan; Mohammed Elsafy; Binh Hoang; Rebecca Lampley; Aparna Kolhekar; Hyung Koo; Catherine Luke; Mamodikoe Makhene; Seema Nayak; Rhonda Pikaart-Tautges; Paul C Roberts; Janie Russell; Elisa Sindall; Jim Albert; Pratap Kunwar; Mat Makowski; Evan J Anderson; Amer Bechnak; Mary Bower; Andres F Camacho-Gonzalez; Matthew Collins; Ana Drobeniuc; Venkata Viswanadh Edara; Srilatha Edupuganti; Katharine Floyd; Theda Gibson; Cassie M Grimsley Ackerley; Brandi Johnson; Satoshi Kamidani; Carol Kao; Colleen Kelley; Lilin Lai; Hollie Macenczak; Michele Paine McCullough; Etza Peters; Varun K Phadke; Paulina A Rebolledo; Christina A Rostad; Nadine Rouphael; Erin Scherer; Amy Sherman; Kathy Stephens; Mehul S Suthar; Mehgan Teherani; Jessica Traenkner; Juton Winston; Inci Yildirim; Lee Barr; Joyce Benoit; Barbara Carste; Joe Choe; Maya Dunstan; Roxanne Erolin; Jana Ffitch; Colin Fields; Lisa A Jackson; Erika Kiniry; Susan Lasicka; Stella Lee; Matthew Nguyen; Stephanie Pimienta; Janice Suyehira; Michael Witte; Hamilton Bennett; Nedim Emil Altaras; Andrea Carfi; Marjorie Hurley; Brett Leav; Rolando Pajon; Wellington Sun; Tal Zaks; Rhea N Coler; Sasha E Larsen; Kathleen M Neuzil; Lisa C Lindesmith; David R Martinez; Jennifer Munt; Michael Mallory; Caitlin Edwards; Ralph S Baric; Nina M Berkowitz; Eli A Boritz; Kevin Carlton; Kizzmekia S Corbett; Pamela Costner; Adrian Creanga; Nicole A Doria-Rose; Daniel C Douek; Britta Flach; Martin Gaudinski; Ingelise Gordon; Barney S Graham; LaSonji Holman; Julie E Ledgerwood; Kwanyee Leung; Bob C Lin; Mark K Louder; John R Mascola; Adrian B McDermott; Kaitlyn M Morabito; Laura Novik; Sarah O'Connell; Sijy O'Dell; Marcelino Padilla; Amarendra Pegu; Stephen D Schmidt; Wei Shi; Phillip A Swanson; Chloe A Talana; Lingshu Wang; Alicia T Widge; Eun Sung Yang; Yi Zhang; James D Chappell; Mark R Denison; Tia Hughes; Xiaotao Lu; Andrea J Pruijssers; Laura J Stevens; Christine M Posavad; Michael Gale; Vineet Menachery; Pei-Yong Shi
Journal:  Science       Date:  2021-08-13       Impact factor: 63.714

6.  Results of the RENAISSANCE Study: REsponse to BNT162b2 COVID-19 vacciNe-short- And long-term Immune reSponSe evAluatioN in health Care workErs.

Authors:  Arianna Pani; Valeria Cento; Chiara Vismara; Daniela Campisi; Federica Di Ruscio; Alessandra Romandini; Michele Senatore; Paolo Andrea Schenardi; Oscar Matteo Gagliardi; Simona Giroldi; Laura Zoppini; Mauro Moreno; Matteo Corradin; Oscar Massimiliano Epis; Nicola Ughi; Irene Cuppari; Roberto Crocchiolo; Marco Merli; Marco Bosio; Silvano Rossini; Massimo Puoti; Francesco Scaglione
Journal:  Mayo Clin Proc       Date:  2021-08-30       Impact factor: 7.616

7.  Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce.

Authors:  Jocelyn Keehner; Lucy E Horton; Nancy J Binkin; Louise C Laurent; David Pride; Christopher A Longhurst; Shira R Abeles; Francesca J Torriani
Journal:  N Engl J Med       Date:  2021-09-01       Impact factor: 91.245

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.